MedPath

Obatoclax

Generic Name
Obatoclax
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C20H19N3O
CAS Number
803712-67-6
Unique Ingredient Identifier
QN4128B52A
Background

Obatoclax has been used in trials studying the treatment of AML, Leukemia, Myelofibrosis, Hodgkin's Lymphoma, and Mantle-Cell Lymphoma, among others.

Associated Conditions
-
Associated Therapies
-

Obatoclax Mesylate, Rituximab, and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Phase 1
Withdrawn
Conditions
Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
Nodal Marginal Zone B-cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Splenic Marginal Zone Lymphoma
Interventions
First Posted Date
2010-11-10
Last Posted Date
2013-06-06
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT01238146
Locations
🇺🇸

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center, Columbus, Ohio, United States

Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia

Phase 1
Terminated
Conditions
Acute Leukemias of Ambiguous Lineage
Acute Undifferentiated Leukemia
Angioimmunoblastic T-cell Lymphoma
Blastic Phase Chronic Myelogenous Leukemia
Childhood Burkitt Lymphoma
Childhood Chronic Myelogenous Leukemia
Childhood Diffuse Large Cell Lymphoma
Childhood Immunoblastic Large Cell Lymphoma
Childhood Nasal Type Extranodal NK/T-cell Lymphoma
Cutaneous B-cell Non-Hodgkin Lymphoma
Interventions
First Posted Date
2009-07-08
Last Posted Date
2014-05-01
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
22
Registration Number
NCT00933985
Locations
🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

Lurie Children's Hospital-Chicago, Chicago, Illinois, United States

🇺🇸

Indiana University Medical Center, Indianapolis, Indiana, United States

and more 17 locations

Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase 1
Terminated
Conditions
Refractory Multiple Myeloma
Stage III Multiple Myeloma
Stage I Multiple Myeloma
Stage II Multiple Myeloma
Interventions
Drug: obatoclax mesylate
Drug: bortezomib
Other: laboratory biomarker analysis
First Posted Date
2008-07-22
Last Posted Date
2015-01-12
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
11
Registration Number
NCT00719901
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

Phase 1
Terminated
Conditions
Stage I Chronic Lymphocytic Leukemia
Stage III Chronic Lymphocytic Leukemia
Leukemia
Prolymphocytic Leukemia
Stage IV Chronic Lymphocytic Leukemia
B-cell Chronic Lymphocytic Leukemia
Stage II Chronic Lymphocytic Leukemia
Refractory Chronic Lymphocytic Leukemia
Interventions
Drug: obatoclax mesylate
Drug: fludarabine phosphate
Biological: rituximab
Other: laboratory biomarker analysis
First Posted Date
2008-02-11
Last Posted Date
2013-09-30
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
28
Registration Number
NCT00612612
Locations
🇺🇸

Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

Phase 1
Terminated
Conditions
Adult Non-Hodgkin Lymphoma
Recurrent Adult Diffuse Large Cell Lymphoma
Recurrent Grade 1 Follicular Lymphoma
Recurrent Grade 2 Follicular Lymphoma
Recurrent Grade 3 Follicular Lymphoma
Recurrent Mantle Cell Lymphoma
Recurrent Marginal Zone Lymphoma
Recurrent Small Lymphocytic Lymphoma
Interventions
Drug: obatoclax mesylate
Drug: bortezomib
Other: laboratory biomarker analysis
Other: pharmacological study
First Posted Date
2007-10-02
Last Posted Date
2015-12-04
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
18
Registration Number
NCT00538187
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Obatoclax Mesylate and Topotecan Hydrochloride in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer or Advanced Solid Tumors

Phase 1
Completed
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Recurrent Small Cell Lung Cancer
Interventions
Drug: obatoclax mesylate
Drug: topotecan hydrochloride
Other: laboratory biomarker analysis
First Posted Date
2007-08-27
Last Posted Date
2015-05-05
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
22
Registration Number
NCT00521144
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital, Baltimore, Maryland, United States

🇺🇸

Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath